

15 May 2024

India | Equity Research | Q4FY24 results review

Cera Sanitaryware

Sanitaryware

Margin surprises positively; near-term demand environment remains tepid

Cera Sanitaryware (CRS) has reported Q4FY24 consolidated revenue growth of 2.5% YoY (+25% QoQ; 3-year CAGR of 7.8%) with sanitaryware revenue declining 2% YoY, faucetware growing 10% YoY, while tiles revenue declined 10% YoY. OPM increased 41bps YoY (+330bps QoQ) driven by lower A&P expenses and other cost optimisation measures (other expenses declining 357bps YoY) resulting in EBIDTA/APAT growth of 5.0%/12.6% YoY, respectively. Management stated demand is likely to revive post Q1FY25 and has revised revenue guidance of ~INR 29bn to Mar'27 (from Sep'25 earlier). It expects FY25 to be stronger driven by uptick in real estate demand and retail segment. We like CRS led by its significant presence in sanitaryware and faucetware segments, demand for which is set to rise led by an improving housing market. We broadly maintain our PAT estimates and upgrade the stock to **ADD** from Hold with an unchanged Mar'25E TP of INR 7,827, set at 32x Mar'26E P/E.

Revenue growth of 2.5% YoY

CRS' consolidated revenue increased 2.5% YoY (+25% QoQ; 3-year CAGR of 7.8%) with sanitaryware revenue declining ~2% YoY and faucetware growing ~10% YoY (3-year CAGR of ~9% and ~16% respectively), whereas tile segment revenue declined ~10% YoY. Management stated demand was subdued in Q4 and remains so in Q1FY25-TD (due to manpower shortage on account of elections and extreme hot weather conditions), but it may revive post Q1FY25. The company believes its growth trajectory will remain strong as it continues to focus on enhancing the share of luxury SKUs in its product mix. It has now guided for revenue of ~INR 29bn to be achieved by Mar'27 (vs Sep'25 earlier) due to current tepid demand environment, implying a revenue CAGR of ~16% over FY24-27. Its capex plans are on track with complete land acquisition for sanitaryware plant likely to be finalised by Jul'24. In Q4FY24, NWC stood at 59 (-10 days YoY) primarily due to lower inventory days (-7 days YoY). CRS had net cash of ~INR 8.2bn as on FY24.

Operating margin improves on lower A&P and cost efficiencies

CRS's Q4FY24 consolidated OPM increased 41bps YoY (+330bps QoQ) to 17.3% due to lower A&P expense and cost optimisation measures (other expenses down 357bps/455bps YoY/QoQ), while gross margin fell 292bps YoY (-357bps QoQ) due to discount schemes offered to trade. Management refrained from guiding on margins due to uncertain near-term demand and inflationary environment. We have modelled operating margin of 16-16.3% for FY25-26E (vs FY12-FY24 average EBIDTA margin of ~15.2%).

Financial Summary

Y/E March (INR mn)	FY23A	FY24A	FY25E	FY26E
Net Revenue	18,033	18,794	21,248	24,682
EBITDA	2,937	3,033	3,392	4,019
EBITDA %	16.3	16.1	16.0	16.3
Net Profit	1,911	2,402	2,667	3,181
EPS (INR)	146.9	184.7	205.1	244.6
EPS % Chg YoY	32.7	25.7	11.0	19.3
P/E (x)	47.3	37.6	33.9	28.4
EV/EBITDA (x)	28.5	27.1	23.7	19.8
RoCE (%)	16.0	15.1	14.8	15.8
RoE (%)	17.5	19.1	18.6	19.7

Arun Baidarun.baid@icicisecurities.com
+91 22 6807 7235**Sohil Kaura**

sohil.kaura@icicisecurities.com

Market Data

Market Cap (INR)	90bn
Market Cap (USD)	1,082mn
Bloomberg Code	CRS IN
Reuters Code	CERA.BO
52-week Range (INR)	9,782 / 6,551
Free Float (%)	45.0
ADTV-3M (mn) (USD)	2.0

Price Performance (%)	3m	6m	12m
Absolute	(7.8)	(21.8)	(3.6)
Relative to Sensex	(9.3)	(33.1)	(20.8)

Earnings Revisions (%)	FY25E	FY26E
Revenue	0.1	0.2
EBITDA	(3.2)	(2.4)
EPS	0.0	0.0

Previous Reports

14-02-2024: [Q3FY24 results review](#)06-12-2023: [Company Update](#)

Valuation and views

CRS' Q4FY24 operating result has been better than consensus estimates. It has strong net cash balance sheet with healthy growth prospects led by an uptick in housing market and increased demand from home improvement market. We like the company for its comprehensive product portfolio, wide distribution reach and strong brand presence. Upgrade the stock to **ADD** from **Hold** post ~8% correction in the stock price over the last 3 months with an unchanged Mar'25E target price of INR 7,827.

Exhibit 1: Q4FY24 consolidated result review

INR mn	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)	FY24	FY23	YoY (%)
Total revenues	5,488	5,356	2.5%	4,389	25.0%	18,794	18,105	3.8%
Raw Materials	2,701	2,480	8.9%	2,004	34.8%	8,828	8,246	7.1%
% of sales	49.2%	46.3%	292 bps	45.6%	357 bps	47.0%	45.5%	142 bps
Employee exps	581	554	4.9%	567	2.6%	2,309	2,147	7.6%
% of sales	10.6%	10.3%	24 bps	12.9%	-232 bps	12.3%	11.9%	43 bps
Other exp	1,256	1,417	-11.4%	1,204	4.3%	4,624	4,710	-1.8%
% of sales	22.9%	26.5%	-357 bps	27.4%	-455 bps	24.6%	26.0%	-141 bps
Total expenditure	4,538	4,451	2.0%	3,775	20.2%	15,761	15,103	4.4%
% of sales	83%	83.1%	-41 bps	86.0%	-330 bps	83.9%	83%	44 bps
EBITDA	950	905	5.0%	614	54.5%	3033	3002	1.0%
margin (%)	17.3%	16.9%	41 bps	14.0%	330 bps	16.1%	16.6%	-44 bps
Depreciation	96.6	83.4	15.9%	96.6	0.1%	365.5	326.1	12.1%
EBIT	853	821	3.9%	518	64.7%	2,667	2,676	(0.3%)
EBIT Margin (%)	15.5%	15.3%	21 bps	11.8%	374 bps	14.2%	14.8%	-59 bps
Other income	157.3	91.4	72.1%	159.7	-1.5%	595.0	283.8	109.7%
Interest cost	15.5	21.1	-26.8%	15.7	-1.7%	58.2	60.5	-3.8%
PBT	995	891	11.6%	662	50.3%	3204	2899	10.5%
Taxes	237.7	209.8	13.3%	146.6	62.1%	775.3	738.3	5.0%
PAT before minority interest/associates	757	682	11.1%	515	46.9%	2429	2161	12.4%
Less: Minority interest	7.7	4.1	87.9%	6.4	19.7%	23.2	16.5	40.7%
Add: share of profit in associate	0.0	0.0	nm	0.0	nm	0.0	0.0	#DIV/0!
Less: Extraordinaries	0.0	50.0	nm	0.0	nm	15.6	50.0	nm
Reported PAT	749	628	19.4%	509	47.3%	2390	2094	14.1%
APAT	749	666	12.6%	509	47.3%	2402	2131	12.7%

Source: I-Sec research, Company data


Exhibit 2: Q4FY24 standalone result review

INR mn	Q4FY24	Q4FY23	YoY (%)	Q3FY24	QoQ (%)	FY24	FY23	YoY (%)
Total revenues	5,466	5,334	2.5%	4,367	25.2%	18,712	18,032	3.8%
Raw Materials	2,704	2,479	9.1%	2,000	35.2%	8,822	8,218	7.4%
% of sales	49.5%	46.5%	300 bps	45.8%	367 bps	47.1%	45.6%	157 bps
Employee exps	573	545	5.0%	558	2.6%	2,275	2,113	7.7%
% of sales	10.5%	10.2%	25 bps	12.8%	-230 bps	12.2%	11.7%	44 bps
Other exp	1,268	1,426	-11.1%	1,215	4.4%	4,672	4,778	-2.2%
% of sales	23.2%	26.7%	-354 bps	27.8%	-461 bps	25.0%	26.5%	-153 bps
Total expenditure	4,545	4,451	2.1%	3,773	20.5%	15,769	15,108	4.4%
% of sales	83%	83.4%	-29 bps	86.4%	-324 bps	84.3%	83.8%	49 bps
EBITDA	921	883	4.2%	594	55.0%	2943	2923	0.7%
EBITDA margin (%)	16.8%	16.6%	29 bps	13.6%	324 bps	15.7%	16.2%	-49 bps
Depreciation	91.5	77.9	17.5%	91.2	0.4%	343.7	304.4	12.9%
EBIT	829	806	3.0%	503	64.9%	2,599	2,619	-0.8%
EBIT Margin (%)	15.2%	15.1%	7 bps	11.5%	365 bps	13.9%	14.5%	-63 bps
Other income	164.4	97.9	67.9%	159.9	2.9%	611.5	302.3	102.3%
Interest cost	14.3	19.0	-24.8%	14.5	-1.2%	53.0	54.0	-1.9%
PBT	980	884	10.8%	648	51.0%	3158	2867	10.1%
Taxes	229	205	11.8%	140	64.1%	750	721	4.1%
PAT before extraordinary items	750	679	10.4%	509	47.5%	2407	2147	12.1%
Less: extraordinary items	0	50	-100.0%	0	#DIV/0!	16	50	-0.68886
Reported PAT	750	629	19.2%	509	47.5%	2392	2097	14.1%
APAT	750	668	12.4%	509	47.5%	2404	2134	12.6%


Source: I-Sec research, Company data

Takeaways from Q4FY24 earnings conference call


- **Industry size:** Management indicated sanitaryware industry size of ~INR 90-100bn and faucetware industry size of ~INR 140bn.
- **Demand** environment was challenging in Q4FY24 and may remain slightly subdued in Q1FY25 as well due to manpower movement from elections and extreme weather conditions. Post Q1FY25, overall demand should improve.
- **Margin improvement:** Lower A&P expense and other cost optimisation led to lower other expenses which aided margins, despite fall in gross margins (as CRS offered higher discounts to incentivise sales). It expects pricing to roll back to normal levels after Q1FY25.
- **Outlook:** Company has observed a growing consumer trend for luxury property and application of high value products in bathrooms. Also, with higher share of luxury real estate launches coming up, CRS sees good growth opportunities
- CRS will focus on growing its luxury brands like 'Luster' and 'Senator' to cater to customers in luxury segments. It expects 8-10% revenue contribution from these brands by FY27.
- **Pricing:** CRS took 2% price hike in sanitaryware to offset RM inflation in Feb'24.
- **Guidance:** Management has guided for INR 29bn revenue by FY27, at 16% CAGR FY24-27.
- **Gas prices:** In Q4FY24, gas cost sourced from GAIL was INR 28.35/scm (down from ~INR 35.67/scm YoY) and contributed 80% of gas requirement. However, gas cost from Sabarmati gas was INR 50.12/scm (down from INR 57.4/scm YoY) and contributed 20% of gas requirement. **Average blended gas cost for Q4FY24 was INR 32.63/scm.**
- **Working capital days decreased by 10 days YoY to 59 in Q4FY24**, with inventory days at 70 (-7 days YoY), receivable days at 34 (+2 days YoY) and payable days at 45 (+5 days YoY).
- **Capacity expansion and capex:** For greenfield expansion of sanitaryware plant, the company has completed 80% of land acquisition at a cost of INR 250mn in Mar'24 and the remaining land acquisition is likely in Jul'24, post which it will take 18 months for the plant to operationalise. Management has indicated additional maintenance capex of INR 254mn planned for FY25 for maintenance activities.
- **Product mix:** Sanitaryware formed 51% of revenue (-2% YoY) with faucetware at 38% (+10% YoY), tiles at 9% (-10% YoY) and wellness at 2% (+21% YoY) in Q4FY24. Sanitaryware reported revenue of INR 9.59bn (flat YoY) with faucetware at INR 6.71bn (+9.8% YoY), tiles at INR 1.91bn (+0.8% YoY) and wellness at INR 0.38bn (+21.1% YoY) in FY24.
- **Tier-wise mix:** In Q4FY24, tier-1 contributed 34%, tier-2 contributed 21% and tier-3 contributed 45% of revenue.
- **Segment mix:** Premium segment contributed 41% (vs 43% YoY) of revenue with mid-level at 35% (vs 31% YoY) and entry segment at 24% (vs 26% YoY) in Q4FY24. Premium segment contributed 43% (vs 43% YoY) of revenue with mid-level at 33% (vs 30% YoY) and entry segment at 24% (vs 27% YoY) in FY24.
- **Utilisation:** Sanitaryware plant ran at 82% utilisation, while faucetware plant ran at 90% utilisation in Q4FY24.
- **Branding:** A&P expenses stood at INR 632mn in FY24 (vs INR 570mn YoY) and INR 154mn in Q4FY24 (vs INR 240mn YoY). Management expects INR 630-650mn as A&P expenses in FY25.
- **Distribution:** Management reported 6,200 dealers in FY24 (vs 5,400 dealers YoY) and 19,300 retailers in FY24 vs 14,550 in FY23.

Exhibit 3: Consolidated quarterly revenue



Source: I-Sec research, Company data

Exhibit 4: Consolidated quarterly EBITDA margin (%)



Source: I-Sec research, Company data

Exhibit 5: Standalone quarterly revenue



Source: I-Sec research, Company data

Exhibit 6: Standalone quarterly EBITDA margin (%)


Source: I-Sec research, Company data

Exhibit 7: Quarterly revenue breakup


Source: I-Sec research, Company data

Exhibit 8: Segmental revenue growth



Source: I-Sec research, Company data

Valuation

CRS is one of the major organised sanitaryware players in India. Over the years, the company has expanded its product portfolio from sanitaryware to tiles, faucets and wellness goods, becoming a one-stop bathroom solution provider. It has significant presence in tier-2 and tier-3 markets with strong brand name and wide distribution.

CRS is expected to witness revenue/EBIDTA CAGR of 14.6%/15.1%, respectively, during FY24-26E, with continued strong balance sheet and healthy return ratios (RoE of 19.7% in FY26E). We upgrade CRS to **ADD** (from Hold) with an unchanged Mar'25E target price of INR 7,827, set at 32x Mar'26E P/E, in line with the historical 5-year average, 1-year forward P/E.

Exhibit 9: 1-year forward PE band



Source: I-Sec research, Company data

Key downside risks

- Unexpected slowdown in housing market would adversely affect business.
- Higher raw material prices may adversely affect profitability and demand.

Key upside risks

- Sharp decline in raw material prices could result in better-than-expected profitability.
- Better than expected pick-up in demand scenario.

Exhibit 10: Shareholding pattern

%	Sep'23	Dec'23	Mar'24
Promoters	54.5	54.5	54.5
Institutional investors	29.3	29.0	28.5
MFs and others	8.2	8.1	6.3
Insurance	0.2	0.3	0.3
FII	20.9	20.6	21.9
Others	16.2	16.5	17.0

Source: Bloomberg

Exhibit 11: Price chart



Source: Bloomberg

Financial Summary

Exhibit 12: Profit & Loss

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Net Sales	18,033	18,794	21,248	24,682
Operating Expenses	15,096	15,761	17,857	20,663
EBITDA	2,937	3,033	3,392	4,019
EBITDA Margin (%)	16.3	16.1	16.0	16.3
Depreciation & Amortization	326	365	379	409
EBIT	2,611	2,667	3,013	3,611
Interest expenditure	60	58	32	22
Other Non-operating Income	43	595	638	728
Recurring PBT	2,593	3,204	3,619	4,317
Less: Taxes	(738)	(775)	(926)	(1,105)
PAT	1,855	2,429	2,693	3,212
Profit / (Loss) from Associates	-	-	-	-
Less: Minority Interest	(16)	(23)	(26)	(31)
Extraordinaries (Net)	256	(16)	-	-
Net Income (Reported)	2,094	2,390	2,667	3,181
Net Income (Adjusted)	1,911	2,402	2,667	3,181

Source Company data, I-Sec research

Exhibit 13: Balance sheet

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Assets				
Inventories	3,825	3,636	4,158	4,812
Cash & cash eqv.	6,859	8,397	9,971	10,943
Sundry Debtors	1,892	2,026	2,270	2,570
Other Current Assets	596	527	640	744
Trade payables	2,069	1,790	2,146	2,477
Other Current Liabilities	1,958	2,153	2,500	2,888
Net Current Assets	9,145	10,643	12,395	13,703
Investments	31	16	16	16
Net Fixed Assets	3,308	3,629	3,650	4,212
Other Non Current Assets	256	225	225	225
Total Assets	12,739	14,512	16,286	18,155
Liabilities				
Borrowings	253	205	170	50
Other Non Current Liabilities	654	722	754	786
Total Liabilities	907	927	924	836
Equity Share Capital	65	65	65	65
Reserves & Surplus	11,661	13,393	15,143	17,070
Total Net Worth	11,726	13,458	15,208	17,135
Minority Interest	106	128	153	184
Total Liabilities & Net Worth	12,739	14,512	16,286	18,155

Source Company data, I-Sec research

Exhibit 14: Quarterly trend

(INR mn, year ending March)

	Jun-23	Sep-23	Dec-23	Mar-24
Net Sales	4,289	4,637	4,389	5,488
% growth (YOY)	8.0	11.5	-4.1	2.5
EBITDA	704	765	614	950
Margin %	16.4	16.5	14.0	17.3
Other Income	153	125	160	157
Extraordinaries	0	16	0	0
Adjusted Net Profit	563	581	509	749

Source Company data, I-Sec research

Exhibit 15: Cashflow statement

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Operating Cashflow	724	2,946	2,951	3,346
Working Capital Changes	(1,698)	40	(177)	(337)
Capital Commitments	852	(691)	(400)	(970)
Free Cashflow	1,577	2,255	2,551	2,376
Other investing cashflow	50	15	-	-
Cashflow from Investing Activities	902	(676)	(400)	(970)
Issue of Share Capital	0	-	-	-
Inc (Dec) in Borrowings	(13)	(49)	(35)	(120)
Dividend paid	(650)	(780)	(942)	(1,285)
Others	114	97	-	0
Cash flow from Financing Activities	(549)	(733)	(977)	(1,405)
Chg. in Cash & Bank balance	1,077	1,538	1,574	972
Closing cash & balance	6,859	8,397	9,971	10,943

Source Company data, I-Sec research

Exhibit 16: Key ratios

(Year ending March)

	FY23A	FY24A	FY25E	FY26E
Per Share Data (INR)				
Reported EPS	161.0	183.8	205.1	244.6
Adjusted EPS (Diluted)	146.9	184.7	205.1	244.6
Cash EPS	172.0	212.8	234.2	276.0
Dividend per share (DPS)	50.0	60.0	72.5	98.8
Book Value per share (BV)	901.6	1,034.8	1,169.3	1,317.5
Dividend Payout (%)	34.0	32.5	35.3	40.4
Growth (%)				
Net Sales	24.8	4.2	13.1	16.2
EBITDA	26.9	3.3	11.8	18.5
EPS (INR)	32.7	25.7	11.0	19.3
Valuation Ratios (x)				
P/E	47.3	37.6	33.9	28.4
P/CEPS	40.4	32.6	29.7	25.2
P/BV	7.7	6.7	5.9	5.3
EV / EBITDA	28.5	27.1	23.7	19.8
EV / Sales	4.6	4.4	3.8	3.2
Dividend Yield (%)	0.7	0.9	1.0	1.4
Operating Ratios				
Gross Profit Margins (%)	54.3	53.0	51.5	51.8
EBITDA Margins (%)	16.3	16.1	16.0	16.3
Effective Tax Rate (%)	28.5	24.2	25.6	25.6
Net Profit Margins (%)	10.6	12.8	12.6	12.9
NWC / Total Assets (%)	13.6	12.2	11.6	11.7
Net Debt / Equity (x)	(0.6)	(0.6)	(0.6)	(0.6)
Net Debt / EBITDA (x)	(2.2)	(2.7)	(2.9)	(2.7)
Profitability Ratios				
RoCE (%) (post-tax)	16.0	15.1	14.8	15.8
RoE (%)	17.5	19.1	18.6	19.7
Cash Conversion Cycle (on net sales)				
Inventory Turnover Days	77	71	71	71
Receivables Days	38	39	39	38
Payables Days	42	35	37	37

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Arun Baid, MBA; Sohil Kaura, M.Com (Finance); authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Prabodh Avadhoot](mailto:Mr.Prabodh.Avadhoot) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
